已收盘 05-15 16:00:00 美东时间
+0.080
+2.06%
Incannex Healthcare (NASDAQ:IXHL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.79) by 55.7 percent. This is a 94.35 percent increase over losses of $(6.19) per share
05-16 07:07
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has shared an announcemen...
05-12 20:42
Incannex Healthcare Inc. has won the "Best New Technology Solution for Drug Development" award at the 10th annual MedTech Breakthrough Awards for its lead drug candidate, IHL-42X, an oral therapy for obstructive sleep apnea (OSA). IHL-42X combines dronabinol and acetazolamide to target key drivers of OSA, showing significant reductions in AHI and improvements in sleep quality in Phase 2 trials. The award highlights Incannex's innovative approach ...
05-12 12:00
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has provided an announcem...
04-22 20:34
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April
04-22 20:08
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
03-27 21:17
BRIEF-Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position Incannex Healthcare Inc IXHL.O : INCANNEX REACTIVATES SHARE REPURCHASE PROGRAM, UNDERSCORING CONFIDENCE IN VALUATION AND STRATEGIC POSITION Source text: ID:nGNX8G1VpZ Further company cove
03-27 20:05
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program,
03-27 20:03
Incannex Healthcare joins the AASM Foundation's Corporate Recognition Program and sponsors a research grant for junior investigators focused on sleep apnea. The company advances IHL-42X, an oral treatment for obstructive sleep apnea, with recent milestones including positive Phase 2 results, FDA Fast Track designation, and the onset of the DReAMzz Phase 2 study. The partnership supports innovation and the next generation of sleep medicine researc...
03-25 12:00
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no
03-18 20:04